Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy J Price

Showing results (111-120 of 153) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2011
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal CancerTimothy J Price, Jennifer E Hardingham, Chee K Lee, et al.
Expert Review of Anticancer Therapy|August 21, 2014
Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013Timothy J Price, Eva Segelov, Matthew Burge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2021
Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II StudyJennifer Mooi, Fiona Chionh, Peter Savas, et al.
Expert Review of Anticancer Therapy|April 27, 2013
Current opinion on optimal treatment for colorectal cancerTimothy J Price, Eva Segelov, Matthew Burge, et al.
Clinical Colorectal Cancer|January 1, 2019
Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20J Connor Wells, Dongsheng Tu, Lillian L Siu, et al.
Cancers|September 27, 2025
Cell Line-Dependent Internalization, Persistence, and Immunomodulatory Effects of <i>Staphylococcus aureus</i> in Triple-Negative Breast CancerSima Kianpour Rad, Runhao Li, Kenny K L Yeo, et al.
Expert Review of Anticancer Therapy|March 25, 2016
Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015Timothy J Price, Subotheni Thavaneswaran, Matthew Burge, et al.
Cancers|June 24, 2022
Young-Onset Gastrointestinal Adenocarcinoma Incidence and Survival Trends in the Northern Territory, Australia, with Emphasis on Indigenous PeoplesMia Shepherdson, Shalem Leemaqz, Gurmeet Singh, et al.
Expert Review of Anticancer Therapy|March 19, 2020
Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019David K Lau, Matthew Burge, Amitesh Roy, et al.
Biomolecules|January 25, 2025
Enhancement of Doxorubicin Efficacy by Bacopaside II in Triple-Negative Breast Cancer CellsSima Kianpour Rad, Kenny K L Yeo, Runhao Li, et al.
Pageof 16

Showing results (111-120 of 153) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2011
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal CancerTimothy J Price, Jennifer E Hardingham, Chee K Lee, et al.
Expert Review of Anticancer Therapy|August 21, 2014
Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013Timothy J Price, Eva Segelov, Matthew Burge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2021
Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II StudyJennifer Mooi, Fiona Chionh, Peter Savas, et al.
Expert Review of Anticancer Therapy|April 27, 2013
Current opinion on optimal treatment for colorectal cancerTimothy J Price, Eva Segelov, Matthew Burge, et al.
Clinical Colorectal Cancer|January 1, 2019
Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20J Connor Wells, Dongsheng Tu, Lillian L Siu, et al.
Cancers|September 27, 2025
Cell Line-Dependent Internalization, Persistence, and Immunomodulatory Effects of <i>Staphylococcus aureus</i> in Triple-Negative Breast CancerSima Kianpour Rad, Runhao Li, Kenny K L Yeo, et al.
Expert Review of Anticancer Therapy|March 25, 2016
Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015Timothy J Price, Subotheni Thavaneswaran, Matthew Burge, et al.
Cancers|June 24, 2022
Young-Onset Gastrointestinal Adenocarcinoma Incidence and Survival Trends in the Northern Territory, Australia, with Emphasis on Indigenous PeoplesMia Shepherdson, Shalem Leemaqz, Gurmeet Singh, et al.
Expert Review of Anticancer Therapy|March 19, 2020
Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019David K Lau, Matthew Burge, Amitesh Roy, et al.
Biomolecules|January 25, 2025
Enhancement of Doxorubicin Efficacy by Bacopaside II in Triple-Negative Breast Cancer CellsSima Kianpour Rad, Kenny K L Yeo, Runhao Li, et al.
Pageof 16